6th international Symposium on Hepatitis Care in Substance Users Jersey City/New York, USA 6 - 8 September 2017

Poster Listing

To view the poster please click on the title of presentation. Note; only the posters provided are available.

Poster NumberFirst NameLast Name Paper Title
1MatthewAkiyamaHepatitis C Resistance-Associated Substitutions among People who Inject Drugs Treated with Direct- Acting Antiviral-Containing Regimens in the Prevail Study
2ImtiazAlamImproving Cascade of Hepatitis C Care through Linkage to C Care Program [LTC]
3MarianneAlanko BloméAssessment of Hepatitis C at the Malmö Needle Exchange Program, Sweden
4ArshiaAlimohammadiHCV-Infected People who Inject Drugs (PWID): Long-term Engagement to Prevent Recurrent Viremia (RV) in Patients that Received IFN-Based Therapies
5ArshiaAlimohammadiReversal of Fibrosis Following Successful HCV Therapy among HIV/HCV Co-Infected People who Use Drugs
6KateAllardiceImplementation of a Nurse–Led Model of Care to Treat People who Inject Drugs (PWID) for HCV in the Community
7ArmanAltugReducing Viral Hepatitis Transmission in Persons Experiencing Incarceration through Education and Peer-Based Interventions
8OlgaAnagnostouOvercoming Barriers to CHC Treatment: A Meaningful and Effective Collaboration of a Public Sector Organization with a Patients’ Community Organization
9Andreea AdelinaArtenieCocaine Injection Patterns over Time among People who Inject Drugs in Montreal, and the Link with Risk of HCV Infection
10Andreea AdelinaArtenieRate of Opiate Agonist Initiation According to Preferred Opioid of Abuse among People who Inject Drugs in Montreal, Canada
11AliceAsherEstimating the Cost of a Comprehensive Syringe Service Program in the United States
12ElisabethAvrilHIV HCV HBV Screening and Fibroscan Sessions in Paris DCR
13SaharBajisAcceptability of Point of Care Finger-Stick and Venepuncture Hepatitis C Virus Testing among People who Inject Drugs and Homeless People
14TaraBeaulieuHIV Serostatus and Having a Regular Physician for Hepatitis C among People who Inject Drugs
15MargueriteBeiserFIB-4 Index and APRI to Assess Shifting Prevalence of Advanced Fibrosis in Homeless Adults with Hepatitis C in Boston
16YashnaBhutaniThe Community Pop-Up Clinic (CPC): A Strategy to Engage HCV-Infected People who Use Drugs (PWUD) in Long-Term Healthcare
17RobBielenMortality of HCV Infected People who Inject Drugs in Limburg: A 20-Year Follow-Up Study
18Dan
Bigg
International NGO Collaboration as a Catalyst to Effective Harm Reduction Practices Regarding Viral Hepatitis Prevention, Screening and Cure.
19Lynne
Biggart
Combined Hepatology/Addictions Advanced Fibrosis Clinic Leads to High Attendance Rates amongst Cohort with History of Failure to Engage with Service
20Ruthie
Birger
Modeling the Impact of HCV Therapy on People who Inject Drugs in Ho Chi Minh City, Vietnam
21Alison
Boyle
Successful Treatment of Patients on Opiate Replacement Therapy Utilising Partial Directly Observed Therapy of DAAs in Community Pharmacies
22Catherine
Brogan
An Evidence Review - Integrated Community Based HCV Treatment Models, Enabling People who Inject Drugs to Access HCV Treatment
23Nathalie
Brunner
Hepatitis C Treatment with Direct-Acting Antivirals for Patients in Opioid Substitution Treatment and Heroin Assisted Treatment: Real-Life Data
24Erika
Castro
A Cost-Effectiveness Analysis of Increasing HCV Screening in PWID in Switzerland Using Rapid Antibody Saliva and Dried Blood Spot Testing
25Qiushi
Chen
Resource Allocation for Hepatitis C Elimination: An Analytical Modeling Framework
26Athina
Chounta
Epidemiological and Compliance Data for IV Drug Users from a Hepatology Department in Greece
27Jennie
Coleman
From Testing to Viral Suppression: The HCV Care Continuum at an Urban Harm Reduction Agency and Syringe Exchange in Philadelphia
28Anton
Colman
Increase in Hepatitis C Treatment in a Marginalized and Disadvantage Community in Adelaide, South Australia.
29Brian
Conway
Comorbidities among HIV/HCV Coinfected People who Inject Drugs (PWID): A Retrospective Cohort Study
30Des
Crowley
A Report on Phase One of the Prison Based Hepatitis C Seek and Treat Project in Ireland
31Des
Crowley
Evaluating the Impact of Prison Based Peer Workers on Hepatitis C Virus Screening in an Irish Prison
32Des
Crowley
Hepatitis C; Homelessness as a Barrier to Engagement
33Monica
Desai
Measures of Hepatitis C (HCV) Incidence in the Era of HCV Prevention
34John
Dillon
Efficacy and Safety of Simeprevir-Containing Hepatitis C Therapy in Patients on Opiate Substitution Therapy
35El Hadji Bara
Diop
CoDisen ANRS 12334: Cohort Study on People who Use Injectable Drugs in Senegal, First Results on HIV and Hepatitis Prevalence
36James
Dunne
HCV Prevention and Needle and Syringe Programs: Peer Voices Enhancing Service Delivery
37Benjamin
Eckhardt
HCV Treatment for People who Inject Drugs Co-Located within a Needle Syringe Program
38Benjamin
Eckhardt
Unsafe Places: Syndemic Risk Factors for HCV Seropositivity in Young People who Inject Drugs, New York City
39Aryan
Esmaeili
Correlates of Higher Female to Male HCV Infection among People who Inject Drugs: Results from The International Multi-Cohort Inc3 Collaborative
40Oluwaseun
Falade-Nwulia
Having more HIV Infected Network Members in Care is Associated with Increased HCV Treatment Uptake among People who Inject Drugs
41Jason
Farrell
DCR and Harm Reduction Program HCV Capacity Building
42Mary
Fenech
Clinicians Attitudes Towards the Treatment of Patients with Hepatitis C who are Injecting Drug Users (CATHPIN)
43Dawn
Fishbein
"Oral Opiate Prescription use as a Risk Factor for Hepatitis C in those Tested Outside of the Birth Cohort
44Hannah
Fraser
Impact of Scaling-Up HCV Prevention and Treatment Interventions among People who Inject Drugs in San Francisco vs Perry County Kentucky
45Hannah
FraserInvestigating the Impact of Scaling-Up Screening, Treatment, and Prevention Interventions Targeting Priority Groups for Hepatitis C Virus Elimination in Pakistan
46Ragnheidur Hulda
Fridriksdottir
Outcomes of Treatment for Hepatitis C Virus Infection in the Prison Setting in the Traphepc (Treatment as Prevention for Hepatitis C) Program in Iceland
47Stelliana
Goutzamanis
Experiences of Uncertainty and Stress Following Fibrosis Assesment in People who Inject Drugs Living with Hepatitis C, Melbourne, Australia
48Jason
Grebely
Efficacy and Safety of Sofosbuvir-Based Direct-Acting Antiviral (DAA) Therapies for HCV Infection in Patients Receiving Opioid Substitution Therapy (OST)
49Jason
Grebely
Self-Reported Competency Related to Testing, Management and Treatment of HCV Infection among Physicians Prescribing Opioid Agonist Therapy: The C-Scope Study
50Binod
Gurung
Scaling-Up Coverage & Quality Of HIV & Viral Hepatitis Prevention Targeted to Most-at-Risk Population
51Ed
Hall
How to Set-Up a HCV Treatment Program within a Busy Methadone Program in Sydney, Australia.
52Matthew
Hickman
Evaluation of an Intervention Designed to Increase Diagnosis and Treatment of Patients with Hepatitis-C Virus Infection in Drug Treatment Settings
53Karli
Hochstatter
Promoting Hepatitis C Virus Screening and Linkage to Care for Opioid Users through a Mobile-Health System: Early Experience from a Randomized Trial
54Emmanuelle
Huchet
Substitution Treatment for Opioides is a Key Factor for HCV Cure in Drug Users
55Samantha
Jones
Redefining Preparedness for Hepatitis C Treatment from the Peer Perspective
56John
Jost
HCV Knowledge and Risks Behaviors among Young Suburban People who Inject Drugs
57Martin
Kåberg
Insufficient HCV Testing in an OST Clinic in Stockholm Calls for Changes in Testing Routines
58Martin
Kåberg
Incidence of HCV among Participants in the Stockholm Needle Exchange Program
59Donald
Kotler
Factors Affecting Hepatitis C Virus Seropositivity in the Inner City
60Charikleia
Kranidioti
Direct Acting Antiviral (DAA) Therapy in People who Inject Drugs (PWID) with Advanced Hepatitis C Virus (HCV) Related Liver Disease
61Charikleia
Kranidioti
Direct-Acting Antiviral Therapy in Patients with Advanced Disease: Comparison of SVR Rates Between People who Inject Drugs (PWID) and non-PWID
62Charikleia
Kranidioti
Severity and Correlates of Liver Fibrosis in Hepatitis C-Infected People who Inject Drugs and Patients Infected by Other Routes
63Lise
Lafferty
Does Australia's Policy Landscape Support HCV Treatment as Prevention in the Prison Setting in the New DAA Era?
64Sarah
Larney
A Cross-Sectional Study of the Association Between Self-Perceived HCV Status and Receptive Syringe Sharing among Australians who Regularly Inject Drugs
65Jeffrey
Lazarus
Hepatitis C Testing, Care and Treatment at Harm Reduction Centres in the European Union: A 28-Country Survey of Service Providers
66Jeffrey V
Lazarus
Assessing the Policy Response to Hepatitis C in the Nordic Countries: The Hep-Nordic Study 106
67Yuridia
Leyva
Per-Contact Infectivity of Hepatitis C Virus Acquisition in Association with Receptive Needle Sharing Exposures in a Prospective Cohort of Young Injection Drug Users
68Danielle
Melissa
MacGregor
Hordes
Health Insurance Barriers to Direct Acting Antivirals (DAAs) in a U.S. Integrated Hepatitis C Virus Infection (HCV)/Methadone Maintenance Program (MMP)
69Louis
Macgregor
Widespread PrEP Coverage May Increase the Prevalence of Hepatitis C within Men who Have Sex with Men
70Gisela
Macphail
Cascade of Hepatitis C (HCV) Care at CUPS - an Inner-City Clinic in Calgary, Alberta, Canada
71Matthew
Madin-Warburton
Cost-Effectiveness of Ledipasvir/Sofosbuvir for the Treatment of Chronic Hepatitis C in the UK: A Dynamic Transmission Modelling Approach
72Amy
Malaguti
Reducing Injecting Drug Use Risks by Providing Foil to Smoke Heroin: A Service Improvement Pilot Evaluation
73Amy
Malaguti
Staff’s Attitudes Toward Injecting Drug Users and Hepatitis C
74Natasha
Martin
The Cost-Effectiveness of General Population HCV Screening in India
75Natasha
Martin
"Incidence of Hepatitis C among HIV-Infected Men who Have Sex with Men (MSM), 2000–2015
76Mojca
Maticic
Stage of Liver Fibrosis and Linkage to Care in HCV-Infected People who Inject Drugs: Results from National Study in Slovenia
77Mojca
Maticic
Development of National Strategies, Plans and Guidelines for HCV Treatment in PWID Between 2013 and 2016 in 33 European Countries
78Loris
Mattox
Harm Reduction Strategies to Combat Hepatitis and the Opioid Epidemic
79Jorge
Mera
The Road to Hepatitis C Elimination in a Tribal Health System
80Håvard
Midgard
The HCV Care Cascade among People who Inject Drugs in A Norwegian Low-Threshold Setting: The Major Barrier is Fibrosis Restrictions
81Rozalyn
Milne
DAA TDAA Therapy for HCV Infection among People with a Substance Use History Attending an Inner-City Community Health Centre - Victoria, Canada
82Nanor
Minoyan
Neighbourhood Risk Environments and Hepatitis C Virus Infection among Persons who Inject Drugs in Montreal

83Sandi
Mitchell
WITHDRAWN
84John
Moloney
Near- Patient Serial Transient Elastography (STE) Improves Hepatitis C Treatment Uptake among Patients on Opioid Substitution Treatment (OST)
85Alberto
Moriggia
Barriers to Widespread Hepatitis C Treatment among People who Inject Drugs: Data from the Sammsu Cohort
86Alberto
Moriggia
Models Of Care For The Management Of Hepatitis C Among People Who Inject Drugs In Southern Switzerland: Role Of Nurses
87Meghan
Morris
Estimating Hepatitis C Burden in San Francisco: Quantifying the Disproportionate Impact on People who Inject Drugs
88Meghan
Morris
Hepatitis C Treatment Uptake and Completion among Young Adults who Inject Drugs: Identifying Gaps to Inform Response
89Karen
Mulligan
Potential Health Outcome and Efficiency Gains of Consolidating the Hepatitis-C Screening and Linkage to Care Cascade In Substance Abuse Programs
90Sarjita
Naik
HCV: The Silent Epidemic an Educational Intervention
91Gero
Niess
Real Word Effectiveness of Interferon-Free Sofosbuvir Based Regimens in Patients with Opioid Substitution Therapy – German Hepatitis C Registry Data
92Gero
Niess
Realworld Evidence for Improvement of Clinical Symptoms and Wellbeing of OST Patients after IFN-Free Sofosbuvir– Based Regimen Therapy: DHC-R Data
93Eileen
O Connor
Real Life HCV Treatment Data from an Inner City Dublin Hospital Clinic
94Eileen
O'Connor
HepLink: Integrating Hepatitis C Treatment in Primary Care
95Margaret
O'Sullivan
"Evaluation of a Community-Based Hepatitis C Virus Service [Project ITTREAT (Integrated Community Based Test–Stage–Treat) for People Who Inject Drugs (PWID)]"
96Anne L.H.
Øvrehus
Low Test Uptake of Hepatitis C and HIV among the Young Seeking Drug Use Treatment in Denmark Between 1996-2015.
97Nikolaos
Papadopoulos
Efficacy of Pegylated-Interferon and Ribavirin (Pr) in Persons who Inject Drugs (PWID): 3-Years’ Experience Of one Inpatient Rehabilitation Facility
98Alisa
Pedrana
A Partnership Approach to Implementing an Elimination Program for Hepatitis C: A Story from Down Under
99Nicola
Perry
Hepfriend; A Dublin Based Peer Facilitated Model of Engagement in the HCV Care Pathway
100Chelsie
Porter
HCV Services and Syringe Exchange Programs: Partnering to Improve Access to Care for People who Inject Drugs
101Andrew
Radley
Ensuring Pragmatic Trials Work: The Precis-2 Tool to Aid the Design of SUPERDOT-C, a Cluster Randomised Controlled Trial in Pharmacy
102Phillip
Read
Treatment Adherence among People who Inject Drugs Taking Directly Observed Direct Acting Antiviral Therapy at Kirketon Road Centre
103Phillip
Read
Client Acceptability and Feasibility of Expanded Access to Direct Acting Antiviral Therapy for Hepatitis C at the Kirketon Road Centre
104Phillip
ReadTreatment of Aboriginal and Torres Strait Islander Clients with Direct Acting Antivirals at the Kirketon Road Centre
105Phillip
Read
Incorporating Overdose Management into Routine Care of People who Inject Drugs who are Undergoing Hepatitis C Treatment with Direct Acting Antivirals
106Noreen
Reed
Liver Health Event: An Innovative Approach to Improve Hepatitis C Screening and Linkage to Care in Indigeneous Communities
107Andre JeanRemyHepatitis C in Prisons in France, Situational Analysis in 2015: Efficient Screening, Undertreatment
108Farah
Riazi
Psychiatric and Substance Use Characteristics are not Barriers for Medication Approval and Achieving SVR in an Urban HCV population
109Jacqui
Richmond
Spreading The Word: The Role Of Hepatitis C Education In Achieving Elimination
110Elana
Rosenthal
Baseline Characteristics of An Urban Cohort of Patients with Chronic HCV and Active IDU: Challenges and Possibilities
111Elise
Roy
Injection of Prescription Opioids: A Matter of Concern for Hepatitis C Prevention
112Eberhard
Schatz
WITHDRAWN
113
Nick
Scott
Modelling Hepatitis C Virus Elimination and Monitoring Policies in Iceland
114Nick
Scott
Recommendations for Hepatitis C Virus Testing among People who Inject Drugs in Australia
115Miranda
Sedillo
Hepatitis C Treatment Outcomes Utilizing the ECHO Modeltm in New Mexico Prisons
116Kathleen
Seneca
Elimination of Hepatits C Virus (HCV) Requires Identification of those Infected - A Successful Identification Process at Acute Detox Hospital
117Nikrant
Shrestha
Health Promotion; A Continuing Role for Peer Support Workers in Drug Health Service Liver Clinics
118Ayorinde
Soipe
Prevalence of Hepatitis C Screening, Testing and Care Experiences among Young Adults who Use Prescription Opioid Non-Medically in Rhode Island
119Ayorinde
Soipe
Chronic Hepatitis C Virus (HCV) Burden in Rhode Island: Modelling Treatment Scale-Up and Elimination
120Sunil
Solomon
Cost-Saving of Integrating HCV Testing into HIV Testing Programs for PWID Using Respondent-Driven Recruitment
121Monica
Sousa
Hepatitis C Treatment in People Receiving Opioid Substitution Therapy - A Difficult Population?
122Jack
Stone
Modelling the Role of Incarceration on HCV Transmission amongst People who Inject Drugs in Kentucky and Impacts of Reducing Incarceration
123Marie
Sutton
Meet them Where they are: Successful Implementation of Hepatitis C Screening and Linkage in Substance Abuse Clinics, Georgia, USA
124Jan
Tait
Eradicate-C Study: Treating Chaotic Drug Users to Eliminate Hepatitis C – The Final Report.
125Jan
Tait
Hepatitis C Treatment in People Who Inject Drugs (PWIDs): The End of Venous Blood Monitoring?
126Donna
Thain
What do You Need to Plan and Implement a Hepatitis C (HCV) Elimination Project in a Geographical Region: Worked Example
127Clara
Thierfelder
High Treatment Uptake Despite Limited Treatment Access at the Basel Centre for Addiction Medicine
128Rachel
Thomson
Re-Engagement of Clients with Hepatitis C Attending a Substance Misuse Service Following an Education Day to Community Psychiatric Nurses (CPNs)
129Judith
Tsui
Characterization of a Population with Hepatitis C Infection in a U.S. State Prison
130Mark
Tyndall
Hepatitis C Virus (HCV) Mortality Attribution by Birth Cohort: British Columbia Hepatitis Testers Cohort (BC-HTC)
131Kjersti
Ulstein
Feasibility and Efficacy of Direct-Acting Antiviral Therapy for Treatment of Hepatitis C Infection in a Low Threshold Setting
132Daniela
Van Santen
Frequent Delayed Hepatitis B Spontaneous Clearance Among High Risk Groups
133Josephine
Walker
The Changing Role of Injecting Drug Use in the Hepatitis C Virus Epidemic in Georgia and Paths to Elimination
134Sally
Watkinson
Community Prescribing of Hepatitis C Treatment – A Nurse- Led Model to Increase Treatment Uptake by People who Inject Drugs
135Jeffrey
Weiss
Motivation, Information, and Substance Use are Barriers to HCV Treatment Initiation in HIV/HCV Co-Infected Patients
136Ryan
Westergaard
Addressing the Hepatitis C Epidemic in Criminal Justice Settings through Academic-Public Health Partnerships
137Tessa
Windelinckx
C-Buddies: Challenges in the Comprehensive Approach of Hepatitis C Management among People who Use Drugs
138Robert
Wong
Markov Model to Evaluate Health Outcomes of Sofosbuvir/Velpatasvir/Voxilaprevir for Salvage Treatment of Patients with Chronic Hepatitis C in the US
139Ioannis
Xynotroulas
DAAS Show very High Efficacy in IDUS with Chronic Hepatitis C, Receiving Opioid Replacement with Buprenorphine in Central Greece
140Tara
Zeagman
Linking PWUD, People who Use Drugs, into Hepatitis C Care